The analgesic activity of acetyl-L-carnitine (ALCAR) in neuropathic pain is well established. By contrast, its potential efficacy in the relief of acute pain has not been reported. The antinociceptive effect of ALCAR was, therefore, examined in the mouse hotplate and abdominal constriction tests, and in the rat paw-pressure test. ALCAR (100 mg kg1 s.c. twice daily for seven days) produced an increase of the pain threshold in both mice and rats. ALCAR was also able to reverse hyperalgesia induced by kainic acid and NMDA administration in the mouse hot-plate test. The antinociception produced by ALCAR was prevented by the unselective muscarinic antagonist atropine, the M1 selective antagonists pirenzepine and S-(-)-ET126, and by the choline uptake inhibitor hemicholinium-3 (HC-3). By contrast the analgesic effect of ALCAR was not prevented by the opioid antagonist naloxone, the GABAB antagonist CGP 35348, the monoamine synthesis inhibitor (a)-methyl-p-tyrosine, and the Gi-protein inactivator pertussis toxin. Moreover, ALCAR antinociception was abolished by pretreament with an antisense oligonucleotide (aODN) against the M1 receptor subtype, administered at the dose of 2 nmol per single i.c.v injection. On the basis of the above data, it can be postulated that ALCAR exerted an antinociceptive effect mediated by a central indirect cholinergic mechanism. In the antinociceptive doserange, ALCAR did not impair mouse performance evaluated by the rota-rod and hole-board tests.

ACETYL-L-CARNITINE INDUCES MUSCARINIC ANTINOCICEPTION IN MICE AND RATS / C. GHELARDINI; N. GALEOTTI; M. CALVANI; L. MOSCONI; R. NICOLAI; A. BARTOLINI;. - In: NEUROPHARMACOLOGY. - ISSN 0028-3908. - STAMPA. - 43:(2002), pp. 1180-1187. [10.1016/S0028-3908(02)00225-3]

ACETYL-L-CARNITINE INDUCES MUSCARINIC ANTINOCICEPTION IN MICE AND RATS

GHELARDINI, CARLA;GALEOTTI, NICOLETTA;BARTOLINI, ALESSANDRO
2002

Abstract

The analgesic activity of acetyl-L-carnitine (ALCAR) in neuropathic pain is well established. By contrast, its potential efficacy in the relief of acute pain has not been reported. The antinociceptive effect of ALCAR was, therefore, examined in the mouse hotplate and abdominal constriction tests, and in the rat paw-pressure test. ALCAR (100 mg kg1 s.c. twice daily for seven days) produced an increase of the pain threshold in both mice and rats. ALCAR was also able to reverse hyperalgesia induced by kainic acid and NMDA administration in the mouse hot-plate test. The antinociception produced by ALCAR was prevented by the unselective muscarinic antagonist atropine, the M1 selective antagonists pirenzepine and S-(-)-ET126, and by the choline uptake inhibitor hemicholinium-3 (HC-3). By contrast the analgesic effect of ALCAR was not prevented by the opioid antagonist naloxone, the GABAB antagonist CGP 35348, the monoamine synthesis inhibitor (a)-methyl-p-tyrosine, and the Gi-protein inactivator pertussis toxin. Moreover, ALCAR antinociception was abolished by pretreament with an antisense oligonucleotide (aODN) against the M1 receptor subtype, administered at the dose of 2 nmol per single i.c.v injection. On the basis of the above data, it can be postulated that ALCAR exerted an antinociceptive effect mediated by a central indirect cholinergic mechanism. In the antinociceptive doserange, ALCAR did not impair mouse performance evaluated by the rota-rod and hole-board tests.
2002
43
1180
1187
C. GHELARDINI; N. GALEOTTI; M. CALVANI; L. MOSCONI; R. NICOLAI; A. BARTOLINI;
File in questo prodotto:
File Dimensione Formato  
75.ALCAR neuroph 2002.pdf

accesso aperto

Tipologia: Versione finale referata (Postprint, Accepted manuscript)
Licenza: Open Access
Dimensione 194.01 kB
Formato Adobe PDF
194.01 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/311633
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 47
  • ???jsp.display-item.citation.isi??? 42
social impact